Press Releases
-
May 14, 2019Company Posts Highest Ever Quarterly Revenue...May 7, 2019Live Conference Call and Webcast Scheduled for May 14, 2019, at 9:00 a.m. ET...Apr 24, 2019Australian TGA Approval Decision Expected in Early 2020...Apr 16, 2019ENGLEWOOD, CO / ACCESSWIRE / April 16, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the formal appointment of Steven Boyd, Founder and Chief Investment Officer of Armistice Capital, to the Aytu BioScience board of directors. As previously announced in Decem...Mar 27, 2019Interim Results Demonstrated Preservation of Sperm Parameters After Six Months of Treatment with Nasally-Administered Natesto Testosterone Gel...Mar 19, 2019Natesto ''MY-T study'' - First Study to Demonstrate Improvement of Low T Symptoms in Men After Switching to Natesto from Topical Testosterone Gels...Mar 14, 2019Data to be Presented on Ongoing Natesto Spermatogenesis Study, Study Evaluating the Effect of Natesto Nasal Testosterone on Male Fertility Parameters...Mar 6, 2019Aytu Assumes Milestone & Royalty-Based Licensing Agreement with SUDA Pharmaceuticals to Sublicense ZolpiMist Outside of the United States and Canada...Feb 7, 2019Company Posts Highest Ever Quarterly Revenue...Jan 31, 2019Live Conference Call and Webcast Scheduled for February 7, 2019, at 9:00 a.m. ET...